Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. - Isenberg D; Furie R; Jones NS; Guibord P; Galanter J; Lee C; McGregor A; Toth B; Rae J; Hwang O; Desai R; Lokku A; et al. (Arthritis & rheumatology (Hoboken, N.J.), 2021)